TempraMed Partners with Super-Pharm, Israel’s Leading Pharmacy Chain to Commence a National Product Roll Out Strategy

Super-Pharm operates nationwide, serving millions of consumers annually

Vancouver, British Columbia–(Newsfile Corp. – February 10, 2026) – TempraMed Technologies Ltd. (CSE: VIVI) (FSE: 9DY) (“TempraMed” or the “Company“), a medical-technology innovator transforming how temperature-sensitive medications are stored and managed, is excited to announce the rollout of its products across Super-Pharm, Israel’s largest and most prominent pharmacy and health-retail chain, operating nationwide and serving millions of consumers annually.

The rollout makes TempraMed’s portfolio of temperature-protection products broadly accessible to patients managing insulin, epinephrine auto-injectors, and other temperature-sensitive medications through one of the country’s most trusted healthcare platforms.

This expansion represents a meaningful commercialization milestone for TempraMed, significantly increasing visibility, point-of-care access, product education and consumer adoption potential in a core market where chronic conditions such as diabetes and anaphylaxis are prevalent.

“This is an exciting inflection point for TempraMed, as we continue to execute on our defined commercialization strategy in Israel, a core market for us, and as well Globally,” said Ron Nagar, CEO of TempraMed. “Super-Pharm is a cornerstone of healthcare in Israel and rolling out our products to Super-Pharm substantially expands our consumer reach and reinforces TempraMed’s position as the category leader in personal medication temperature protection and management. This is another step in executing our strategy to scale through high-traffic retail and healthcare channels. We will now have access to millions of potential customers across Israel through our national pharmacy roll out strategy as well as access to large HMO customers.”

Strategic Significance

The Super-Pharm rollout complements TempraMed’s recent institutional and pharmacy-based expansions and further strengthens its defined, multi-channel distribution strategy, which includes:

• Global Healthcare Payors, networks and HMOs
• National retail pharmacy chains in core markets
• Online and direct-to-consumer platforms

The placement within Super-Pharm provides a combination of product accessibility, education, and validation, supporting sustained demand and repeat customer purchases. This, together with the recent roll out to Maccabi Pharm provides adoption and support from two significant national pharmacy chains and reinforces TempraMed’s brand leadership in medication protection.

The Company views Israel as a strategic launch and validation market for broader international expansion, with successful retail rollouts serving as a blueprint for additional partnerships in Europe, North America, and other high-growth regions.

About TempraMed Technologies Ltd.

TempraMed Technologies Ltd. Is a global medical device company with a portfolio of innovative, temperature-controlled medication storage solutions. Founded with the mission to safeguard the effectiveness of life-saving medications, TempraMed develops patented, FDA-registered, thermal insulation devices that work 24/7 without batteries or external power. With a product line already in market including VIVI Cap, VIVI Cap Smart, VIVI Epi, and VIVI Med, TempraMed enables patients and healthcare providers to confidently manage temperature-sensitive medications anywhere, anytime. With operations in North America, Europe, and Asia, TempraMed will continue to expand globally offering a solution for medication protection and adherence.

Cautionary Statements

This press release contains “forward-looking statements or information”. Forward-looking statements can be identified by words such as: anticipate, intend, plan, goal, seek, believe, project, estimate, expect, strategy, future, likely, may, should, will and similar references to future periods. Examples of forward-looking statements in this press release include, but are not limited to, statements regarding: the anticipated benefits and scope of the Super-Pharm retail rollout across Israel; the Company’s ability to drive consumer awareness, education, and adoption of its products through national retail pharmacy channels; expectations regarding sustained demand and repeat customer purchases resulting from the Super-Pharm partnership; the Company’s ability to expand through institutional healthcare channels, including HMOs, payors, and additional retail pharmacy partners; the strengthening of the Company’s brand presence and category leadership in medication temperature protection; the Company’s multi-channel distribution strategy, including global healthcare payors, national retail pharmacy chains, and direct-to-consumer platforms; the use of the Israeli market as a strategic launch and validation market for broader international expansion; and the Company’s ability to replicate the retail rollout model in Europe, North America, and other high-growth regions. Forward-looking statements are neither historical facts nor assurances of future performance. Instead, they are based only on our current beliefs, expectations and assumptions regarding the future of our business, future plans and strategies, projections, anticipated events and trends, the economy and other future conditions. Because forward-looking statements relate to the future, they are subject to inherent uncertainties, risks and changes in circumstances that are difficult to predict and many of which are outside of our control. Our actual results and financial condition may differ materially from those indicated in the forward-looking statements. Important factors that could cause our actual results to differ materially from those indicated in the forward-looking statements include, among others, the Company’s ability to maintain and expand its commercial relationship with Super-Pharm; risks related to the success and scalability of the national retail pharmacy rollout; the Company’s ability to generate sustained consumer demand and repeat purchases through the Super-Pharm pharmacy network; the Company’s ability to secure additional partnerships with retail pharmacy chains, HMOs, payors, and institutional partners in Israel and internationally; risks related to market acceptance and adoption of the Company’s temperature-protection products by consumers and healthcare providers; the Company’s ability to manage supply chain, logistics, and distribution across a national retail pharmacy network; regulatory and compliance risks in Israel and other international markets; the adequacy of the Company’s cash flow and earnings to support ongoing commercialization efforts; the availability of future financing and/or credit; competition from existing or new entrants in the temperature-controlled medication storage market; general economic, market, or business conditions in Israel and globally; currency exchange rate fluctuations; loss of key employees and consultants; and other risks described in the Company’s public filings.

Any forward-looking statement made by us in this press release is based only on information currently available to us and speaks only as of the date on which it is made. Except as required by applicable securities laws, we undertake no obligation to publicly update any forward-looking statement, whether written or oral, that may be made from time to time, whether as a result of new information, future developments or otherwise.

To view the source version of this press release, please visit https://www.newsfilecorp.com/release/283343